What CHIP actually is
CHIP means a small group of your blood stem cells have picked up mutations as you age. These are not cancer. But they are also not harmless.
The cells with these mutations make more copies of themselves than their neighbors. Over years, they grow into a larger share of your blood supply.
More than 10% of people over 70 carry CHIP. Doctors often find it by accident when they run gene tests for other reasons.
The heart connection nobody saw coming
For decades, heart disease was blamed on the usual suspects. Cholesterol. Blood pressure. Smoking. Diabetes.
But here's the twist. People with CHIP have a 1.5 to 2 times higher risk of coronary heart disease and early death, even after accounting for those classic risks.
That is a big deal. It means a blood test, not a cholesterol panel, may flag a serious heart threat that current screening misses.
How old blood cells hurt the heart
Think of your immune cells as a cleanup crew patrolling your blood vessels. They normally remove damaged cells and quiet down inflammation.
CHIP-mutated cells act differently. They behave like an overheated alarm system that will not shut off.
The most common mutations hit four genes: TET2, DNMT3A, ASXL1, and JAK2. These genes normally help cells know when to calm their inflammatory response.
When they break, immune cells called macrophages flip into a pro-inflammatory state. They crank up signals called NLRP3, IL-1 beta, and IL-6.
Those inflammatory signals speed up atherosclerosis, the process where plaque builds up in arteries. They also make plaques more likely to rupture, which is what causes most heart attacks.
The same signals scar the heart muscle itself. That scarring, called fibrosis, can lead to heart failure.
So CHIP is not just a marker. It is an active participant in heart damage.
Not all mutations are equal
Here is where things get interesting.
TET2 mutations carry the highest heart risk. They also seem to respond best to anti-inflammatory drugs.
DNMT3A mutations, though more common, have a weaker link to heart disease. They may work through different pathways that researchers are still mapping.
This is a major shift. It means two people with CHIP could need very different care depending on which gene is mutated.
This doesn't mean CHIP testing is ready for routine clinical use.
The drug clue from an unexpected trial
A few years ago, a large trial called CANTOS tested canakinumab, a drug that blocks the IL-1 beta inflammatory signal. It was designed for heart attack prevention in general.
Later analyses looked at people in the trial who happened to have TET2 mutations. Those patients appeared to benefit more than others.
Colchicine, an old gout drug that also tamps down inflammation, has shown a similar pattern in follow-up studies. The evidence is early but promising.
What doctors are studying now
The review that inspired this article calls for a new field: cardio-hematology. That means cardiologists and blood specialists working together on shared patients.
The dream is mutation-guided care. If you carry a TET2 mutation, your doctor might add an anti-inflammatory drug alongside standard heart medicines. If you have DNMT3A, the plan might look different.
None of this is standard practice yet.
If you are over 70 and generally healthy, you do not need to rush out for CHIP testing. No guidelines recommend it for screening.
But if you have had a heart attack, unexplained heart failure, or blood test abnormalities, ask your doctor whether CHIP could be playing a role. Research clinics and academic centers are starting to pay attention.
Keep doing what already works: control blood pressure, don't smoke, manage cholesterol, stay active. These still matter, CHIP or no CHIP.
The honest limitations
Most CHIP research comes from people of European ancestry. Data in other populations is thin.
There are no large, prospective trials that sort patients by mutation before assigning treatment. Until those exist, mutation-guided therapy is informed guessing.
And CHIP testing is not cheap or widely available outside research.
Trials designed around specific CHIP mutations are the next step. Researchers want to know whether blocking inflammation early can prevent heart events in people who carry these mutations but have no symptoms yet.
If those trials succeed, a simple blood test could reshape how we predict and prevent heart disease. The bone marrow, long ignored by cardiologists, may become a routine target of heart care.
